Normal view
-
cs.AI, q-bio.NC updates on arXiv.org
-
FlowPIE: Test-Time Scientific Idea Evolution with Flow-Guided Literature Exploration
arXiv:2603.29557v1 Announce Type: new Abstract: Scientific idea generation (SIG) is critical to AI-driven autonomous research, yet existing approaches are often constrained by a static retrieval-then-generation paradigm, leading to homogeneous and insufficiently divergent ideas. In this work, we propose FlowPIE, a tightly coupled retrieval-generation framework that treats literature exploration and idea generation as a co-evolving process. FlowPIE expands literature trajectories via a flow-guid
-
cs.AI, q-bio.NC updates on arXiv.org
-
LatentPilot: Scene-Aware Vision-and-Language Navigation by Dreaming Ahead with Latent Visual Reasoning
arXiv:2603.29165v1 Announce Type: cross Abstract: Existing vision-and-language navigation (VLN) models primarily reason over past and current visual observations, while largely ignoring the future visual dynamics induced by actions. As a result, they often lack an effective understanding of the causal relationship between actions and how the visual world changes, limiting robust decision-making. Humans, in contrast, can imagine the near future by leveraging action-dynamics causality, which impr
LatentPilot: Scene-Aware Vision-and-Language Navigation by Dreaming Ahead with Latent Visual Reasoning
-
cs.AI, q-bio.NC updates on arXiv.org
-
DIAL: Decoupling Intent and Action via Latent World Modeling for End-to-End VLA
arXiv:2603.29844v1 Announce Type: cross Abstract: The development of Vision-Language-Action (VLA) models has been significantly accelerated by pre-trained Vision-Language Models (VLMs). However, most existing end-to-end VLAs treat the VLM primarily as a multimodal encoder, directly mapping vision-language features to low-level actions. This paradigm underutilizes the VLM's potential in high-level decision making and introduces training instability, frequently degrading its rich semantic represe
DIAL: Decoupling Intent and Action via Latent World Modeling for End-to-End VLA
-
(Multiomics OR Omics) AND (Pancreatic)
-
Robust transcriptomic hallmarks targeting intratumor heterogeneity in intrahepatic cholangiocarcinoma
Cell Rep Med. 2026 Mar 30:102708. doi: 10.1016/j.xcrm.2026.102708. Online ahead of print.ABSTRACTIntratumor heterogeneity (ITH) undermines transcriptome-based stratification in intrahepatic cholangiocarcinoma (iCCA). Here, we integrate multi-omics data from multi-region, single-region, and single-cell RNA sequencing cohorts to systematically characterize gene expression ITH. We uncover that immune and stromal heterogeneity are primary drivers of ITH, leading to misclassification of a median 27.8
Robust transcriptomic hallmarks targeting intratumor heterogeneity in intrahepatic cholangiocarcinoma
Cell Rep Med. 2026 Mar 30:102708. doi: 10.1016/j.xcrm.2026.102708. Online ahead of print.
ABSTRACT
Intratumor heterogeneity (ITH) undermines transcriptome-based stratification in intrahepatic cholangiocarcinoma (iCCA). Here, we integrate multi-omics data from multi-region, single-region, and single-cell RNA sequencing cohorts to systematically characterize gene expression ITH. We uncover that immune and stromal heterogeneity are primary drivers of ITH, leading to misclassification of a median 27.8% of tumors by existing subtyping systems. To overcome this, we identify a low-intratumor-heterogeneity/high-intertumor-variability (LIHV) gene set and develop an ITH-insensitive classification system defining five subgroups: inflammatory (SI), metabolic (SII), atypical (SIII-1), immune-silent (SIII-2), and neurodegenerative (SIII-3). These subgroups exhibit distinct clinical outcomes, molecular features, immune landscapes, and therapeutic vulnerabilities. GPRC5A and VTCN1 serve as robust immunohistochemical biomarkers for SI and SIII tumors, while serum CEA and CA19-9 identify inflammatory iCCA. Therapeutically, HSP90 inhibition synergizes with anti-PD1 in inflammatory iCCA, whereas combined anti-PD1 and anti-TIM3 suppresses neurodegenerative iCCA. Collectively, our study provides a robust molecular framework and actionable therapeutic strategies for iCCA.
PMID:41916296 | DOI:10.1016/j.xcrm.2026.102708
-
Omics in Hepatocellular
-
The Yin and Yang of tertiary lymphoid structures in primary liver cancer
Cancer Lett. 2026 Mar 27;648:218461. doi: 10.1016/j.canlet.2026.218461. Online ahead of print.ABSTRACTTertiary lymphoid structures (TLSs) have emerged as key regulators of anti-tumor immunity and biomarkers for immunotherapy response in liver cancer, including hepatocellular carcinoma (HCC), intrahepatic cholangiocarcinoma (iCCA), and combined hepatocellular-cholangiocarcinoma (cHCC-iCCA). Advances in single-cell and spatial multi-omics technologies have revealed unprecedented complexity in TLSs
The Yin and Yang of tertiary lymphoid structures in primary liver cancer
Cancer Lett. 2026 Mar 27;648:218461. doi: 10.1016/j.canlet.2026.218461. Online ahead of print.
ABSTRACT
Tertiary lymphoid structures (TLSs) have emerged as key regulators of anti-tumor immunity and biomarkers for immunotherapy response in liver cancer, including hepatocellular carcinoma (HCC), intrahepatic cholangiocarcinoma (iCCA), and combined hepatocellular-cholangiocarcinoma (cHCC-iCCA). Advances in single-cell and spatial multi-omics technologies have revealed unprecedented complexity in TLSs, challenging the traditional binary classification of TLSs as simply "good" or "bad". Their functional diversity appears to be shaped by spatiotemporal context, cellular composition, and maturation status. This review provides a comprehensive synthesis of TLSs in liver cancer, employing the Yin-Yang paradigm to navigate their functional dualism and prognostic contradictions through a detailed analysis of their identification, classification, and spatiotemporal interactions within the TME. Mechanistically, we elucidate how TLS functions are orchestrated by complex interactions between tumor cells, immune cell subsets, stromal components, and systemic factors. Within this framework, key metabolic drivers, notably ATP citrate lyase (ACLY), and signaling axes such as cGAS-STING/mTOR have emerged as pivotal regulators of TLS ontogeny. In addition, we evaluate current preclinical animal models and therapeutic strategies for clinical TLS induction. Furthermore, we have discussed the key unanswered questions in the field, including the three-dimensional architecture of TLSs and the mechanisms by which they establish durable immunological memory independent of the primary tumor. Clinically, TLSs exhibit great promise as prognostic and predictive biomarkers, particularly in the context of immune checkpoint blockade and locoregional therapies. Finally, we identify challenges in standardization, mechanistic understanding, and translational applications, providing directions for future research to harness TLSs for improving liver cancer outcomes.
PMID:41905709 | DOI:10.1016/j.canlet.2026.218461